Latest Insider Transactions at Pear Therapeutics, Inc. (PEAR)
This section provides a real-time view of insider transactions for Pear Therapeutics, Inc. (PEAR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pear Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pear Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2023
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,544,113
-98.02%
|
$0
$0.12 P/Share
|
|
Feb 15
2023
|
Alison Bauerlein Director |
BUY
Grant, award, or other acquisition
|
Direct |
71,428
+50.0%
|
-
|
|
Feb 15
2023
|
Paul Mango Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Shivakumar Rajaraman Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Feb 15
2023
|
Kirthiga Reddy Director |
BUY
Grant, award, or other acquisition
|
Direct |
61,904
+50.0%
|
-
|
|
Feb 15
2023
|
Nancy M Schlichting Director |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+50.0%
|
-
|
|
Feb 15
2023
|
Timothy A Wicks Director |
BUY
Grant, award, or other acquisition
|
Direct |
52,380
+50.0%
|
-
|
|
Jan 20
2023
|
Corey Mc Cann President and CEO |
SELL
Open market or private sale
|
Direct |
34,731
-0.42%
|
$34,731
$1.13 P/Share
|
|
Jan 20
2023
|
Yuri Maricich Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,162
-11.42%
|
$12,162
$1.13 P/Share
|
|
Jan 20
2023
|
Katherine Jeffery Chief People Officer |
SELL
Open market or private sale
|
Direct |
7,096
-46.08%
|
$7,096
$1.13 P/Share
|
|
Jan 20
2023
|
Christopherd T Guiffre CFO, COO, Treas., & Asst. Sec. |
SELL
Open market or private sale
|
Direct |
19,540
-39.47%
|
$19,540
$1.13 P/Share
|
|
Jan 20
2023
|
Erin K. Brenner Chief Product Dev. Officer |
SELL
Open market or private sale
|
Direct |
8,690
-16.71%
|
$8,690
$1.13 P/Share
|
|
Jan 20
2023
|
Julia Strandberg Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,688
-30.72%
|
$12,688
$1.13 P/Share
|
|
Jan 20
2023
|
Ellen Snow VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
8,027
-25.61%
|
$8,027
$1.13 P/Share
|
|
Jan 20
2023
|
Ronan O'Brien CCO, GC, & Secretary |
SELL
Open market or private sale
|
Direct |
12,162
-39.49%
|
$12,162
$1.13 P/Share
|
|
Jan 14
2023
|
Erin K. Brenner Chief Product Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,000
+29.73%
|
-
|
|
Jan 14
2023
|
Yuri Maricich Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+22.43%
|
-
|
|
Jan 14
2023
|
Katherine Jeffery Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,400
+50.0%
|
-
|
|
Jan 14
2023
|
Ronan O'Brien CCO, GC, & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
30,800
+50.0%
|
-
|
|
Jan 14
2023
|
Julia Strandberg Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+44.41%
|
-
|
|
Jan 14
2023
|
Ellen Snow VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,320
+39.33%
|
-
|
|
Jan 14
2023
|
Christopherd T Guiffre CFO, COO, Treas., & Asst. Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
49,500
+50.0%
|
-
|
|
Jan 14
2023
|
Corey Mc Cann President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
88,000
+1.06%
|
-
|
|
Dec 09
2022
|
Lj10 LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
430,000
-6.57%
|
-
|
|
Dec 09
2022
|
Erin K. Brenner Chief Product Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+33.33%
|
$15,000
$1.0 P/Share
|
|
Nov 15
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
63,773
-0.47%
|
$127,546
$2.52 P/Share
|
|
Nov 14
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,128
-0.09%
|
$24,256
$2.79 P/Share
|
|
Nov 11
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,380
-0.22%
|
$88,140
$3.19 P/Share
|
|
Nov 02
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,578
-0.08%
|
$21,156
$2.72 P/Share
|
|
Nov 01
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,467
-0.01%
|
$2,934
$2.8 P/Share
|
|
Oct 31
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
42,164
-0.31%
|
$84,328
$2.78 P/Share
|
|
Sep 16
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
351
-0.0%
|
$351
$1.75 P/Share
|
|
Sep 15
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
272,750
-1.98%
|
$272,750
$1.81 P/Share
|
|
Sep 14
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
285,067
-2.02%
|
$285,067
$1.94 P/Share
|
|
Sep 08
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
304,322
-2.11%
|
$304,322
$1.81 P/Share
|
|
Sep 07
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
154,518
-1.06%
|
$154,518
$1.92 P/Share
|
|
Sep 06
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
311,160
-2.09%
|
$622,320
$2.36 P/Share
|
|
Aug 18
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
222,761
-1.48%
|
$222,761
$1.55 P/Share
|
|
Aug 17
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,077
-0.07%
|
$10,077
$1.71 P/Share
|
|
Aug 16
2022
|
5 Am Partners Iv, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
167,162
-1.1%
|
$167,162
$1.78 P/Share
|
|
May 25
2022
|
Erin K. Brenner Chief Product Dev. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.0 P/Share
|
|
Dec 03
2021
|
Yuri Maricich Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
73,620
+50.0%
|
-
|
|
Dec 03
2021
|
Corey Mc Cann President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
2,672,430
+50.0%
|
-
|
|
Dec 03
2021
|
Corey Mc Cann President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,157,656
+50.0%
|
-
|
|
Dec 03
2021
|
Zack Lynch Director |
BUY
Grant, award, or other acquisition
|
Indirect |
10,766,587
+33.37%
|
$107,665,870
$10.0 P/Share
|
|
Dec 03
2021
|
Andrew J. Schwab Director |
BUY
Grant, award, or other acquisition
|
Indirect |
18,631,771
+38.9%
|
$186,317,710
$10.0 P/Share
|
|
Dec 03
2021
|
Lj10 LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
6,540,000
+50.0%
|
-
|